These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 26481041)

  • 1. Growth inhibitory effect of an injectable hyaluronic acid-tyramine hydrogels incorporating human natural interferon-α and sorafenib on renal cell carcinoma cells.
    Ueda K; Akiba J; Ogasawara S; Todoroki K; Nakayama M; Sumi A; Kusano H; Sanada S; Suekane S; Xu K; Bae KH; Kurisawa M; Igawa T; Yano H
    Acta Biomater; 2016 Jan; 29():103-111. PubMed ID: 26481041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-α2a for liver cancer therapy.
    Xu K; Lee F; Gao SJ; Chung JE; Yano H; Kurisawa M
    J Control Release; 2013 Mar; 166(3):203-10. PubMed ID: 23328125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.
    Benitez A; Yates TJ; Shamaldevi N; Bowen T; Lokeshwar VB
    J Urol; 2013 Jul; 190(1):285-90. PubMed ID: 23228386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme-mediated hyaluronic acid-tyramine hydrogels for the propagation of human embryonic stem cells in 3D.
    Xu K; Narayanan K; Lee F; Bae KH; Gao S; Kurisawa M
    Acta Biomater; 2015 Sep; 24():159-71. PubMed ID: 26112373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells.
    Yu X; Liu F; Zeng L; He F; Zhang R; Yan S; Zeng Z; Shu Y; Zhao C; Wu X; Lei J; Zhang W; Yang C; Wu K; Wu Y; An L; Huang S; Ji X; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Dai Z; Wang X; Liu B; Haydon RC; Luu HH; Gan H; He TC; Chen L
    Cell Physiol Biochem; 2018; 47(3):957-971. PubMed ID: 29843133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma.
    Furuya N; Kamai T; Shirataki H; Yanai Y; Fukuda T; Mizuno T; Nakamura F; Kambara T; Nakanishi K; Abe H; Yoshida K
    Cancer Immunol Immunother; 2011 Jun; 60(6):793-808. PubMed ID: 21350947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyaluronidase-incorporated hyaluronic acid-tyramine hydrogels for the sustained release of trastuzumab.
    Xu K; Lee F; Gao S; Tan MH; Kurisawa M
    J Control Release; 2015 Oct; 216():47-55. PubMed ID: 26260452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
    Sim MY; Huynh H; Go ML; Yuen JSP
    PLoS One; 2017; 12(6):e0178168. PubMed ID: 28582447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
    Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
    Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-6 induces drug resistance in renal cell carcinoma.
    Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
    Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
    Tochizawa S; Masumori N; Yanai Y; Ohmoto Y; Yabuuchi Y; Tsukamoto T
    Biomed Res; 2008 Dec; 29(6):271-8. PubMed ID: 19129670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
    Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
    Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
    Eto M; Kawano Y; Hirao Y; Mita K; Arai Y; Tsukamoto T; Hashine K; Matsubara A; Fujioka T; Kimura G; Shinohara N; Tatsugami K; Hinotsu S; Naito S;
    BMC Cancer; 2015 Oct; 15():667. PubMed ID: 26452347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An injectable hyaluronic acid-tyramine hydrogel system for protein delivery.
    Lee F; Chung JE; Kurisawa M
    J Control Release; 2009 Mar; 134(3):186-93. PubMed ID: 19121348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor effect of local injectable hydrogel-loaded endostatin alone and in combination with radiotherapy for lung cancer.
    Wang N; Gao Q; Tang J; Jiang Y; Yang L; Shi X; Chen Y; Zhang Y; Fu S; Lin S
    Drug Deliv; 2021 Dec; 28(1):183-194. PubMed ID: 33427520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An enzymatically crosslinked collagen type II/hyaluronic acid hybrid hydrogel: A biomimetic cell delivery system for cartilage tissue engineering.
    Torabi Rahvar P; Abdekhodaie MJ; Jooybar E; Gantenbein B
    Int J Biol Macromol; 2024 Nov; 279(Pt 1):134614. PubMed ID: 39127277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzymatic conjugation of a bioactive peptide into an injectable hyaluronic acid-tyramine hydrogel system to promote the formation of functional vasculature.
    Wang LS; Lee F; Lim J; Du C; Wan AC; Lee SS; Kurisawa M
    Acta Biomater; 2014 Jun; 10(6):2539-50. PubMed ID: 24561710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
    Wang X; Zhang L; Goldberg SN; Bhasin M; Brown V; Alsop DC; Signoretti S; Mier JW; Atkins MB; Bhatt RS
    J Transl Med; 2011 Dec; 9():220. PubMed ID: 22188900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
    Rosa R; Damiano V; Nappi L; Formisano L; Massari F; Scarpa A; Martignoni G; Bianco R; Tortora G
    Br J Cancer; 2013 Aug; 109(3):686-93. PubMed ID: 23839492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
    Roulin D; Waselle L; Dormond-Meuwly A; Dufour M; Demartines N; Dormond O
    Mol Cancer; 2011 Jul; 10():90. PubMed ID: 21791089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.